Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells
The improved understanding of the biochemical nature of tumor antigens and the identification of cellular and molecular mechanisms leading to activation of innate and adaptive immune cells have been of paramount importance in the progress of tumor immunology. Studies on the intricate network of inte...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_13816128_v16_n3_p255_Zwirner |
| Aporte de: |
| id |
todo:paper_13816128_v16_n3_p255_Zwirner |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_13816128_v16_n3_p255_Zwirner2023-10-03T16:11:52Z Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells Zwirner, N.W. Croci, D.O. Domaica, C.I. Rabinovich, G.A. Dendritic cells Immunotherapy NK cells T lymphocytes Tumor-immune escape adaptive immunity article cancer immunology cancer immunotherapy cell maturation chronic inflammation dendritic cell human immunomodulation innate immunity lymphocyte differentiation macrophage natural killer cell nonhuman priority journal protein carbohydrate interaction T lymphocyte subpopulation tumor escape Adaptive Immunity Animals Antigens, Neoplasm Chemotherapy, Adjuvant Drug Synergism Humans Immunity, Innate Immunotherapy Neoplasms T-Lymphocytes The improved understanding of the biochemical nature of tumor antigens and the identification of cellular and molecular mechanisms leading to activation of innate and adaptive immune cells have been of paramount importance in the progress of tumor immunology. Studies on the intricate network of interactions between tumor and immune cells have revealed novel regulatory signals, including cell surface inhibitory receptors and costimulatory molecules, intracellular regulatory pathways, immunosuppressive cytokines and proapoptotic mediators, which may operate in concert to orchestrate tumor-immune escape. This emerging portfolio of inhibitory checkpoints can influence the physiology of innate immune cells including dendritic cells, macrophages and natural killer (NK) cells, as well as different subsets of T cells to fine tune their effector function. The synergistic combination of strategies aimed at overcoming regulatory signals and/or stimulating effector pathways, may offer therapeutic advantage as adjuvants of conventional anticancer therapies. Based on this premise, we will discuss here how the control of the effector functions of innate and adaptive immune cells and the manipulation of regulatory pathways, either alone or in combination, could be exploited for therapeutic purposes in cancer patients. © 2010 Bentham Science Publishers Ltd. Fil:Croci, D.O. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. Fil:Domaica, C.I. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_13816128_v16_n3_p255_Zwirner |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Dendritic cells Immunotherapy NK cells T lymphocytes Tumor-immune escape adaptive immunity article cancer immunology cancer immunotherapy cell maturation chronic inflammation dendritic cell human immunomodulation innate immunity lymphocyte differentiation macrophage natural killer cell nonhuman priority journal protein carbohydrate interaction T lymphocyte subpopulation tumor escape Adaptive Immunity Animals Antigens, Neoplasm Chemotherapy, Adjuvant Drug Synergism Humans Immunity, Innate Immunotherapy Neoplasms T-Lymphocytes |
| spellingShingle |
Dendritic cells Immunotherapy NK cells T lymphocytes Tumor-immune escape adaptive immunity article cancer immunology cancer immunotherapy cell maturation chronic inflammation dendritic cell human immunomodulation innate immunity lymphocyte differentiation macrophage natural killer cell nonhuman priority journal protein carbohydrate interaction T lymphocyte subpopulation tumor escape Adaptive Immunity Animals Antigens, Neoplasm Chemotherapy, Adjuvant Drug Synergism Humans Immunity, Innate Immunotherapy Neoplasms T-Lymphocytes Zwirner, N.W. Croci, D.O. Domaica, C.I. Rabinovich, G.A. Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| topic_facet |
Dendritic cells Immunotherapy NK cells T lymphocytes Tumor-immune escape adaptive immunity article cancer immunology cancer immunotherapy cell maturation chronic inflammation dendritic cell human immunomodulation innate immunity lymphocyte differentiation macrophage natural killer cell nonhuman priority journal protein carbohydrate interaction T lymphocyte subpopulation tumor escape Adaptive Immunity Animals Antigens, Neoplasm Chemotherapy, Adjuvant Drug Synergism Humans Immunity, Innate Immunotherapy Neoplasms T-Lymphocytes |
| description |
The improved understanding of the biochemical nature of tumor antigens and the identification of cellular and molecular mechanisms leading to activation of innate and adaptive immune cells have been of paramount importance in the progress of tumor immunology. Studies on the intricate network of interactions between tumor and immune cells have revealed novel regulatory signals, including cell surface inhibitory receptors and costimulatory molecules, intracellular regulatory pathways, immunosuppressive cytokines and proapoptotic mediators, which may operate in concert to orchestrate tumor-immune escape. This emerging portfolio of inhibitory checkpoints can influence the physiology of innate immune cells including dendritic cells, macrophages and natural killer (NK) cells, as well as different subsets of T cells to fine tune their effector function. The synergistic combination of strategies aimed at overcoming regulatory signals and/or stimulating effector pathways, may offer therapeutic advantage as adjuvants of conventional anticancer therapies. Based on this premise, we will discuss here how the control of the effector functions of innate and adaptive immune cells and the manipulation of regulatory pathways, either alone or in combination, could be exploited for therapeutic purposes in cancer patients. © 2010 Bentham Science Publishers Ltd. |
| format |
JOUR |
| author |
Zwirner, N.W. Croci, D.O. Domaica, C.I. Rabinovich, G.A. |
| author_facet |
Zwirner, N.W. Croci, D.O. Domaica, C.I. Rabinovich, G.A. |
| author_sort |
Zwirner, N.W. |
| title |
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| title_short |
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| title_full |
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| title_fullStr |
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| title_full_unstemmed |
Overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| title_sort |
overcoming the hurdles of tumor immunity by targeting regulatory pathways in innate and adaptive immune cells |
| url |
http://hdl.handle.net/20.500.12110/paper_13816128_v16_n3_p255_Zwirner |
| work_keys_str_mv |
AT zwirnernw overcomingthehurdlesoftumorimmunitybytargetingregulatorypathwaysininnateandadaptiveimmunecells AT crocido overcomingthehurdlesoftumorimmunitybytargetingregulatorypathwaysininnateandadaptiveimmunecells AT domaicaci overcomingthehurdlesoftumorimmunitybytargetingregulatorypathwaysininnateandadaptiveimmunecells AT rabinovichga overcomingthehurdlesoftumorimmunitybytargetingregulatorypathwaysininnateandadaptiveimmunecells |
| _version_ |
1807323961048956928 |